| CAS NO: | 969-33-5 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5g | 电议 |
| 10g | 电议 |
| 25g | 电议 |
| 50g | 电议 |
| Molecular Weight (MW) | 323.86 |
|---|---|
| Formula | C21H21N.HCl |
| CAS No. | 969-33-5 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 65 mg/mL (200.7 mM) |
| Water: <1 mg/mL | |
| Ethanol: 20 mg/mL (61.8 mM) | |
| SMILES | CN1CC/C(CC1)=C2C3=CC=CC=C3C=CC4=CC=CC=C/24.Cl |
| Synonyms | Periactin; Eiproheptadine; Periactinol; Cyproheptadine Hydrochloride Sesquihydrate; Dronactin; Ciproheptadina; Peritol |
| In Vitro | In vitro activity: Cyproheptadine is a serotonin and histamine antagonist as well as an antimuscarinic reagent. It is used to treat for postgastrectomy-dumping syndrome, pruritic dermatoses, migraine, anorexia, and pituitary-dependent Cushing's syndrome. The major urinary product of cyproheptadine is cyproheptadine glucuronide, a quaternary ammonium compound. Cyproheptadine has some side effects including sedation, drowsiness, hypotension, tachycardia and blood dyscrasias. |
|---|---|
| In Vivo | a 5-HT2A receptor antagonist, cyproheptadine is found to reverse serotonin-enhanced ADP-induced platelet aggregation in vitro and ex vivo suggesting its antiplatelet and thromboprotective effects. |
| Animal model | |
| Formulation & Dosage | |
| References | J Anal Toxicol. 1998 Jan-Feb;22(1):72-4; PLoS One. 2014 Jan 23;9(1):e87026. |
m.cnreagent.com